Compounds > abiraterone
Page last updated: 2024-09-04

abiraterone and fulvestrant

abiraterone has been researched along with fulvestrant in 2 studies

Compound Research Comparison

Studies
(abiraterone)		Trials
(abiraterone)		Recent Studies (post-2010)
(abiraterone)		Studies
(fulvestrant)		Trials
(fulvestrant)		Recent Studies (post-2010) (fulvestrant)
942978542,7122071,196

Protein Interaction Comparison

ProteinTaxonomyabiraterone (IC50)fulvestrant (IC50)
Estrogen receptorHomo sapiens (human)0.0061
Estrogen receptorRattus norvegicus (Norway rat)0.0059
Progesterone receptorHomo sapiens (human)0.0002
Steroid hormone receptor ERR1Homo sapiens (human)0.002
Bifunctional epoxide hydrolase 2Homo sapiens (human)0.006
Estrogen receptor betaHomo sapiens (human)0.0104
Bile acid receptorHomo sapiens (human)0.79
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)2.6

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Capper, CP; Johnson, MD; Larios, JM; Rae, JM; Sikora, MJ1

Other Studies

2 other study(ies) available for abiraterone and fulvestrant

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
    Breast cancer research and treatment, 2016, Volume: 157, Issue:1

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Receptors, Estrogen

2016